News on research and diagnostic development for pathogenic diseases.
Under the EUA, the lab is authorized to detect SARS-CoV-2 in specimens collected from individuals suspected of having COVID-19 by their healthcare provider.
After around six months, Genetic Signatures anticipates merging its SARS-CoV-2 test with a respiratory disease testing kit.
Color is opening a lab dedicated to SARS-CoV-2 testing and adapting its software infrastructure to enable physicians to order tests and return results.
The companies have signed on to a new public-private initiative organized by Wisconsin's governor intended to increase the state's testing capacity.
The firm said the BARDA funding will support scale-up of a molecular test to facilitate management of the coronavirus pandemic cycle.
